You are describing a specific chemical compound, likely a synthetic molecule, with the following structural features:
* **1-(4-bromophenyl)-4-[1-naphthalenyl(oxo)methyl]-3-pyrazolecarboxylic acid ethyl ester**
This compound is likely a **pyrazole derivative** that incorporates:
* **A pyrazole ring:** A five-membered heterocyclic ring containing two nitrogen atoms.
* **A 4-bromophenyl group:** A benzene ring substituted with a bromine atom at the para (4) position.
* **A 1-naphthalenyl(oxo)methyl group:** This is a naphthalene ring (two fused benzene rings) linked to a carbonyl group (C=O) which in turn is linked to a methyl group (CH3).
* **A carboxylic acid ethyl ester group:** This is a -COOCH2CH3 group attached to the pyrazole ring.
**Why it is important for research**
You did not provide information on why this specific compound is important for research. However, pyrazole derivatives are known for their wide range of biological activities and potential applications, including:
* **Pharmaceuticals:** Pyrazoles are often found in drugs for various conditions like anti-inflammatory, anticonvulsant, analgesic, and anticancer therapies.
* **Agriculture:** Some pyrazoles act as herbicides, fungicides, and insecticides.
* **Materials Science:** Pyrazoles can be used in the synthesis of polymers, dyes, and other materials.
**To understand the specific importance of the compound you mentioned, you would need to:**
1. **Identify the research context:** What study or field is this compound relevant to?
2. **Determine its biological or chemical properties:** Is it an inhibitor of a specific enzyme? Does it exhibit a particular pharmacological activity? Is it a building block for other molecules?
Once you have this information, you can understand why this specific compound is important for research.
ID Source | ID |
---|---|
PubMed CID | 1214563 |
CHEMBL ID | 1384689 |
CHEBI ID | 107308 |
Synonym |
---|
smr000164057 |
MLS000544767 , |
ethyl 1-(4-bromophenyl)-4-(1-naphthoyl)-1h-pyrazole-3-carboxylate |
AJ-916/13002017 |
CHEBI:107308 |
ethyl 1-(4-bromophenyl)-4-(naphthalene-1-carbonyl)pyrazole-3-carboxylate |
HMS2393I08 |
1-(4-bromophenyl)-4-(1-naphthoyl)pyrazole-3-carboxylic acid ethyl ester |
bdbm49494 |
1-(4-bromophenyl)-4-[1-naphthalenyl(oxo)methyl]-3-pyrazolecarboxylic acid ethyl ester |
ethyl 1-(4-bromophenyl)-4-naphthalen-1-ylcarbonyl-pyrazole-3-carboxylate |
cid_1214563 |
CHEMBL1384689 |
Q27185531 |
Class | Description |
---|---|
naphthalenes | Any benzenoid aromatic compound having a skeleton composed of two ortho-fused benzene rings. |
carbonyl compound | Any compound containing the carbonyl group, C=O. The term is commonly used in the restricted sense of aldehydes and ketones, although it actually includes carboxylic acids and derivatives. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Cruzipain | Trypanosoma cruzi | Potency | 39.8107 | 0.0020 | 14.6779 | 39.8107 | AID1476 |
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 6.7456 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
BRCA1 | Homo sapiens (human) | Potency | 14.1254 | 0.8913 | 7.7225 | 25.1189 | AID624202 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 16.3601 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
TDP1 protein | Homo sapiens (human) | Potency | 12.2798 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 4.1095 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
ras-related protein Rab-9A | Homo sapiens (human) | Potency | 3.5481 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 1.9953 | 0.0079 | 8.2332 | 1,122.0200 | AID2551 |
geminin | Homo sapiens (human) | Potency | 10.3336 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 31.6228 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
lamin isoform A-delta10 | Homo sapiens (human) | Potency | 6.3096 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
nuclear factor NF-kappa-B p105 subunit isoform 1 | Homo sapiens (human) | EC50 (µMol) | 3.0020 | 0.0590 | 5.5596 | 27.2100 | AID1241 |
transcription factor p65 isoform 1 | Homo sapiens (human) | EC50 (µMol) | 3.0020 | 0.0590 | 5.5596 | 27.2100 | AID1241 |
Estrogen receptor beta | Mus musculus (house mouse) | EC50 (µMol) | 3.0020 | 0.0590 | 5.5596 | 27.2100 | AID1241 |
Estrogen receptor | Mus musculus (house mouse) | EC50 (µMol) | 3.0020 | 0.0590 | 5.5596 | 27.2100 | AID1241 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |